U.S. Veterinary Pain Management Market Size, Share & Forecast 2026–2032

ID: MR-11625 | Published: November 2026
Download PDF Sample

Report Highlights

  • ✓Country: United States
  • ✓Market: U.S. Veterinary Pain Management Market
  • ✓Market Size 2024: USD 1.82 billion
  • ✓Market Size 2032: USD 2.92 billion
  • ✓CAGR: 6.1%
  • ✓Base Year: 2025
  • ✓Forecast Period: 2026–2032
Market Growth Chart
Want Detailed Insights - Download Sample
Analyst Findings and Recommendations
FINDING 01
Monoclonal Antibodies Reshaping Prescribing: Zoetis's Librela, FDA-approved in May 2023 for canine osteoarthritis pain, has moved injectable biologic therapy into general practice, displacing daily NSAID dosing and creating a recurring-revenue model.
FINDING 02
Opioid Growth Assumption Overstated: Conventional wisdom assumes opioid demand will expand with pain awareness. The opposite is occurring: DEA controlled-substance registration burdens and state prescription monitoring mandates are steering clinics toward unscheduled NSAIDs and monoclonal antibodies, with buprenorphine demand flattening.
ANALYST RECOMMENDATION

Analyst Recommendation — Lock Injectable Supply Early: Distributors and multi-site practice groups should lock multi-year supply agreements for injectable osteoarthritis analgesics before Q1 2027, when further monoclonal competitors are expected to enter. Early contracts protect margins against intensifying generic meloxicam pricing.

Veterinary Pain Management in the U.S.: Market Overview

The U.S. veterinary pain management market generated an estimated USD 1.82 billion in 2024, spanning non-steroidal anti-inflammatory drugs, opioid and partial agonist analgesics, local anesthetics, and monoclonal antibodies for osteoarthritis. Companion animals account for the large majority of revenue, with canine osteoarthritis the single largest indication. The Food and Drug Administration's Center for Veterinary Medicine (CVM) reviews all new animal drugs under the Federal Food, Drug, and Cosmetic Act, which determines which products reach clinics.

Government has been the dominant force in shaping the market's structure, while the private sector has led on product innovation. The Animal Medicinal Drug Use Clarification Act of 1994 enabled extra-label prescribing, sustaining generic meloxicam and carprofen volume across practices. Private firms such as Zoetis and Elanco have driven pipeline development, while the Controlled Substances Act, administered by the Drug Enforcement Administration, constrains opioid volume and shapes prescribing decisions.

Policy-Driven Growth in U.S. Veterinary Pain Management

Three policy mechanisms drive demand. The Animal Drug Availability Act of 2008 modernized CVM's approval framework, including conditional approval authority. CVM's January 2024 approval of Zoetis's Solensia (frunevetmab) for feline osteoarthritis pain illustrates the mechanism: cats tolerate NSAIDs poorly, so a labeled injectable converts previously undertreated patients into recurring clinic revenue.

The Animal Welfare Act, administered by USDA's Animal and Plant Health Inspection Service under 9 CFR 2.31, requires written pain-relief plans for research animals. The PHS Policy on Humane Care and Use of Laboratory Animals, enforced by NIH's Office of Laboratory Animal Welfare, mandates analgesia in federally funded studies, so institutional animal care committees purchase analgesics as non-discretionary compliance inputs. The Animal Medicinal Drug Use Clarification Act of 1994 adds a third driver through its extra-label cascade under 21 CFR Part 530, which lets clinicians prescribe approved analgesics off-label when no labeled alternative exists.

Regulatory Barriers and Compliance Costs

New analgesics must clear CVM's new animal drug review under Section 512 of the Federal Food, Drug, and Cosmetic Act. Safety, effectiveness, and manufacturing sections commonly add multiple review cycles and several years before launch. Generic entrants file under the abbreviated ANADA route but must still prove bioequivalence and manufacturing comparability. Controlled analgesics add a second layer: buprenorphine is Schedule III and tramadol Schedule IV under the Controlled Substances Act, and DEA registrants must renew registration every three years and complete biennial inventories under 21 CFR 1304.11.

State-level barriers add further cost. Each state's veterinary practice act, such as California's Veterinary Medicine Practice Act under Business and Professions Code Section 4800 et seq., governs dispensing, veterinary-client-patient relationships, and prescription records, and state boards enforce these rules separately. Pharmaceutical disposal is also tightening. EPA's Subpart P hazardous waste pharmaceutical rule, codified at 40 CFR Part 266, prohibits sewering of hazardous waste pharmaceuticals and requires state adoption, adding disposal and staff training costs for clinics and distributors.

Policy-Created Opportunities in the U.S.

Research institutions represent a policy-created niche. Because the PHS Policy and 9 CFR 2.31 require analgesia across federally funded studies, suppliers of extended-duration injectable buprenorphine and long-acting NSAID formulations face non-discretionary demand from institutional animal care programs. Suppliers that document compliance with CVM labeling and USDA reporting requirements win preferred status in institutional procurement.

Disposal compliance creates a second opportunity. EPA's Subpart P rule and state adoption schedules require clinics to manage controlled-substance and pharmaceutical waste through reverse distributors and take-back programs. DEA-registered reverse distributors and waste-management firms can offer compliant collection services, and the DEA's National Take Back Day collections, held each April and October, demonstrate the model that practices are now replicating.

Market at a Glance

MetricValue
Market Size 2024USD 1.82 billion
Market Size 2032USD 2.92 billion
Growth Rate (CAGR)6.1%
Most Critical Decision FactorFederal and state controlled-substance compliance burden on analgesic selection
Largest RegionSouth Region
Competitive StructureConsolidated oligopoly; Zoetis and Elanco hold the majority share

Leading Market Participants

  • Zoetis
  • Elanco Animal Health
  • Boehringer Ingelheim Animal Health
  • Merck Animal Health
  • Dechra Pharmaceuticals
  • Norbrook Laboratories
  • Ceva Animal Health
  • Vetoquinol USA
  • Virbac
  • Covetrus

Regulatory and Policy Environment

The primary legislation governing veterinary pain products is Section 512 of the Federal Food, Drug, and Cosmetic Act, administered by the FDA Center for Veterinary Medicine for new animal drug approvals. It is supplemented by the Animal Drug Availability Act of 2008 and the Animal Drug User Fee Amendments, reauthorized as ADUFA V through fiscal 2028. Key compliance requirements include CVM labeling and adverse event reporting, DEA registration and controlled-substance recordkeeping under the Controlled Substances Act, and extra-label prescribing limits under AMDUCA and 21 CFR Part 530.

Upcoming changes include EPA's Subpart P pharmaceutical waste rule, which states must adopt under their own authority, with adoption timelines running through 2026. ADUFA VI negotiations between FDA and industry precede the 2028 expiry and will set fee-funded review performance goals thereafter. Compared with the European Union, where Regulation (EU) 2019/6 harmonizes veterinary medicinal products and the European Medicines Agency's Committee for Veterinary Medicinal Products centralizes authorization, the U.S. framework is more fragmented, with state practice acts layered atop federal approval. Canada's Veterinary Drugs Directorate under Health Canada applies comparable federal authority with less state variation.

Long-Term Policy Outlook for U.S. Veterinary Pain Management

By 2032, the most consequential policy shift will be ADUFA VI, which determines CVM review capacity for novel analgesic approvals from 2028. Fee-funded performance goals are expected to shorten review timelines for monoclonal antibodies and non-opioid analgesics, accelerating the transition from daily NSAIDs to injectables. Zoetis and Elanco have built regulatory and manufacturing teams specifically around this pipeline.

Controlled-substance policy will shape the product mix more than any single approval. State veterinary prescription monitoring requirements and the continued DEA scheduling of buprenorphine and tramadol will keep opioid volumes constrained. Prescribing is expected to consolidate around NSAIDs and monoclonal antibodies by 2032, with EPA Subpart P compliance costs increasingly absorbed by consolidated practice groups and distributors.

Frequently Asked Questions

The FDA Center for Veterinary Medicine approves new animal drugs under Section 512 of the Federal Food, Drug, and Cosmetic Act. Generic products are approved through abbreviated ANADA filings.
Buprenorphine is Schedule III and tramadol is Schedule IV under the Controlled Substances Act, requiring DEA registration and controlled-substance recordkeeping. Registrants must complete biennial inventories under 21 CFR 1304.11.
AMDUCA permits veterinarians to prescribe approved drugs off-label under 21 CFR Part 530 when no labeled alternative exists. Clinicians must document medical necessity and observe withdrawal requirements for food-producing animals.
EPA's Subpart P rule under 40 CFR Part 266 prohibits sewering of hazardous waste pharmaceuticals in states that have adopted it. Clinics must implement compliant disposal and staff training as state adoption takes effect.
ADUFA V covers fee-funded review through fiscal 2028, and ADUFA VI negotiations between FDA and industry precede that expiry. Negotiation minutes are published during the process, allowing market participants to track proposed review goals.

Market Segmentation

By Product Type
  • NSAIDs
  • Opioids
  • Monoclonal Antibodies
  • Local Anesthetics
  • Adjunctive Analgesics
By End User
  • Companion Animal Clinics
  • Mixed-Animal Practices
  • Veterinary Hospitals
  • Research Institutions
By Distribution Channel
  • Veterinary Distributors
  • Direct-to-Practice Sales
  • Online Pharmacies
  • Retail Pharmacies

Table of Contents

Chapter 01 Methodology and Scope
1.1 Research Methodology
1.2 Scope and Definitions
1.3 Data Sources
Chapter 02 Executive Summary
2.1 Report Highlights
2.2 Market Size and Forecast 2024-2032
Chapter 03 U.S. Veterinary Pain Management - Market Analysis
3.1 Market Overview
3.2 Growth Drivers
3.3 Restraints
3.4 Opportunities
Chapter 04 Product Type Insights
4.1 NSAIDs
4.2 Opioids
4.3 Monoclonal Antibodies
4.4 Local Anesthetics
4.5 Others
Chapter 05 End User Insights
5.1 Companion Animal Clinics
5.2 Mixed-Animal Practices
5.3 Veterinary Hospitals
5.4 Research Institutions
5.5 Others
Chapter 06 Distribution Channel Insights
6.1 Veterinary Distributors
6.2 Direct-to-Practice Sales
6.3 Online Pharmacies
6.4 Retail Pharmacies
6.5 Others
Chapter 07 Competitive Landscape
7.1 Market Players
7.2 Leading Market Participants
7.2.1 Zoetis
7.2.2 Elanco Animal Health
7.2.3 Boehringer Ingelheim Animal Health
7.2.4 Merck Animal Health
7.2.5 Dechra Pharmaceuticals
7.2.6 Norbrook Laboratories
7.2.7 Ceva Animal Health
7.2.8 Vetoquinol USA
7.2.9 Virbac
7.2.10 Covetrus
7.3 Regulatory Environment
7.4 Outlook

Research Framework and Methodological Approach

Information
Procurement

Information
Analysis

Market Formulation
& Validation

Overview of Our Research Process

MarketsNXT follows a structured, multi-stage research framework designed to ensure accuracy, reliability, and strategic relevance of every published study. Our methodology integrates globally accepted research standards with industry best practices in data collection, modeling, verification, and insight generation.

1. Data Acquisition Strategy

Robust data collection is the foundation of our analytical process. MarketsNXT employs a layered sourcing model.

Secondary Research
  • Company annual reports & SEC filings
  • Industry association publications
  • Technical journals & white papers
  • Government databases (World Bank, OECD)
  • Paid commercial databases
Primary Research
  • KOL Interviews (CEOs, Marketing Heads)
  • Surveys with industry participants
  • Distributor & supplier discussions
  • End-user feedback loops
  • Questionnaires for gap analysis

Analytical Modeling and Insight Development

After collection, datasets are processed and interpreted using multiple analytical techniques to identify baseline market values, demand patterns, growth drivers, constraints, and opportunity clusters.

2. Market Estimation Techniques

MarketsNXT applies multiple estimation pathways to strengthen forecast accuracy.

Bottom-up Approach

Country Level Market Size
Regional Market Size
Global Market Size

Aggregating granular demand data from country level to derive global figures.

Top-down Approach

Parent Market Size
Target Market Share
Segmented Market Size

Breaking down the parent industry market to identify the target serviceable market.

Supply Chain Anchored Forecasting

MarketsNXT integrates value chain intelligence into its forecasting structure to ensure commercial realism and operational alignment.

Supply-Side Evaluation

Revenue and capacity estimates are developed through company financial reviews, product portfolio mapping, benchmarking of competitive positioning, and commercialization tracking.

3. Market Engineering & Validation

Market engineering involves the triangulation of data from multiple sources to minimize errors.

01 Data Mining

Extensive gathering of raw data.

02 Analysis

Statistical regression & trend analysis.

03 Validation

Cross-verification with experts.

04 Final Output

Publication of market study.

Client-Centric Research Delivery

MarketsNXT positions research delivery as a collaborative engagement rather than a static information transfer. Analysts work with clients to clarify objectives, interpret findings, and connect insights to strategic decisions.